



Press release

Stockholm, 3 June 2025

Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology

VALIANT Phase 3 data in nephrology after presentation at the ERA congress.

Investors, analysts, and members of the media are invited to a conference call on Thursday, 12 June, at 13:30 CEST, 12:30 GMT, and 08:30 EDT. The call will include a presentation of results and insights from management and Professor Fadi Fakhouri following the European Renal Association (ERA) congress and a Q&A session.

The presentation can be followed live [here](#) or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:

Sweden: +46 8 5051 0031

United Kingdom: +44 207 107 06 13

United States: +1 631 570 56 13

For other countries, please find the details [here](#).

Sobi®

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and [LinkedIn](#).

Contacts

For details on how to contact the Sobi Investor Relations Team, please click [here](#). For Sobi Media contacts, click [here](#).

Gerard Tobin

Head of Investor Relations